Mr. Alan Blake is Chief Executive Officer and a Co-Founder of Nuclein. Prior to his involvement with Nuclein, Mr. Blake was a Co-Founder and CEO of Yorktown Technologies LP, which developed and marketed GloFish®, the world’s first widely commercialized biotech animal. Launched in 2003, GloFish subsequently grew to become the most visible consumer biotech product in the world, available in more than 7,000 retail locations, including Walmart, PetSmart and Petco. GloFish was sold to Spectrum Brands Inc. (NYSE: SPB) in 2017. Before GloFish, Mr. Blake founded and led ClassMap, a venture capitalist funded startup in the online learning space, managing the daily operations of 50 employees. Mr. Blake has also served as a Board Member for numerous companies and nonprofit organizations, including currently serving on the University of Texas at Austin McCombs School of Business Advisory Council. He graduated with highest honors from the University of Texas at Austin with a Bachelor of Business Administration in finance and holds 25 patents.

Mr. Alan Blake is Chief Executive Officer of Nuclein. Prior to his involvement with Nuclein, Mr. Blake was a Co-Founder and CEO of Yorktown Technologies LP, which developed and marketed GloFish®, the world’s first widely commercialized biotech animal. Launched in 2003, GloFish subsequently grew to become the most visible consumer biotech product in the world, available in more than 7,000 retail locations, including Walmart, PetSmart and Petco. GloFish was sold to Spectrum Brands Inc. (NYSE: SPB) in 2017. Before GloFish, Mr. Blake founded and led ClassMap, a venture capitalist funded startup in the online learning space, managing the daily operations of 50 employees. Mr. Blake has also served as a Board Member for numerous companies and nonprofit organizations, including currently serving on the University of Texas at Austin McCombs School of Business Advisory Council. He graduated with highest honors from the University of Texas at Austin with a Bachelor of Business Administration in finance and holds 25 patents.

Mr. Jeffrey Stukuls is Chief Financial Officer of Nuclein. Mr. Stukuls has an accomplished background as a Chief Financial Officer and Chief Operating Officer in the technology development, online retail, and services industries. In addition to co-founding and selling his own businesses, including Medwing.com in 2010, his expertise has centered on raising substantial funding and scaling various businesses. Mr. Stukuls was CFO of TrackingPoint, a technology development company which raised over $80M and grew its first-year revenue to over $11M. Additionally, Mr. Stukuls led rapid-growth efforts at Stampede Consulting, which scaled from a team of 10 to over 1,000 people in its first year. He graduated from Bentley University with a Bachelor of Science in Accountancy and a minor in Computer Information Systems, as well as earned an Entrepreneurial Master’s Program Certificate from the MIT Extension School and the Entrepreneur’s Organization.

Mr. Steven Back is Vice President of Quality and Regulatory Affairs of Nuclein.  Prior to Nuclein, Mr. Back held leadership positions in Quality, Regulatory, Engineering and Manufacturing. During his 14 years at Luminex Corporation, he served as Head of Quality and Regulatory across five North American locations, overseeing Quality Management System enhancements, Regulatory Body audits, Product Submissions, Medical Device Report actions (Recalls), Supplier Quality, Production and Incoming Quality, Design Assurance, Documentation and product control and release. As VP of Manufacturing at Luminex, he led all aspects of instrument and reagent/assay cGMP compliant manufacturing, which included Incoming Quality, Quality Control, Supply Chain, Warehouse, Instrument Assembly and Reagent/Assay manufacturing. Prior to Luminex Corporation, Mr. Back worked at Abbott Laboratories, holding several leadership positions during his 18-year tenure, leading Engineering, Manufacturing, and Quality organizations.  He Graduated with a BSSE from Wright State University, an MSEE from the University of Texas at Arlington, and an MBA from the University of Dallas.

Mr. Todd Bennett is Chief Commercial Officer of Nuclein. Mr. Bennett brings over 30 years of sales and marketing experience in the in-vitro diagnostics and biotechnology industries. Mr. Bennett’s executive leadership expertise spans general commercial development and management, business development, global marketing, strategic planning, sales team growth and development, and customer service across multiple diagnostic channels, Molecular Diagnostics, Point of Care, Clinical Chemistry, Immunoassay (Infectious Diseases & Endocrinology), Blood Bank, Hematology, Diabetes Care and Laboratory Services. Mr. Bennett’s extensive team development and leadership experiences include time spent at Abbott Laboratories, Roche Diagnostics, Immucor, Luminex and most recently, Binx Health. Mr. Bennett holds a B.S. degree in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at The Ohio State University in Columbus, Ohio.

Dr. Charles (Chuck) Collins is Chief Technology Officer of Nuclein. Dr. Collins was with Luminex Corporation for over 18 years, rising rapidly through the organization to Senior Vice President, Research & Development for more than three years and then Senior Vice President, Technology & Innovation for more than two years. Dr. Collins was responsible for all Research and Development activities across Luminex, including Systems R&D, Assay R&D and Clinical Affairs, ATG, Chemistry R&D, and the PMO Group. Combined these groups spanned early Innovation, moving into formal Product Development, Clinical Trials, Design Transfer to Manufacturing, and on -market support of all products. Prior to Luminex Dr. Collins was an Electrical Engineer at the U.S. Army Research Laboratory in Adelphi, MD. He holds a Doctor of Philosophy from The University of Texas at Austin in Solid State Electronics and a Bachelor of Science in Electrical Engineering from Trinity University, San Antonio.

Dr. Jim Hully is Chief Scientific Officer of Nuclein. For the last two decades, he has worked in the IVD sector helping a diverse range of companies clear products through the FDA. Prior to Nuclein, Dr. Hully worked an independent consultant focused on FDA EUA COVID-19 assays, as well as at Nanosphere (now part of DiaSorin), where he led the R&D team developing highly multiplexed IVD assays for 510(k) clearance on the Verigene System. Dr. Hully previously worked at Intelligent MDx, where he patented robust methods for oligo designs resulting in multiple SBIR grants, as well as FDA EUA & 510(k) cleared assays. Dr. Hully’s experience also includes Applied Biosystems (now part of Thermo Fisher Scientific), where he was on the team that launched the novel In Situ PCR system. With post-doctoral work at Genentech and the University of Wisconsin, Madison, Dr. Hully graduated from the University of North Wales, Bangor, with a Bachelor of Science in Zoology, and he earned a Master’s in Science & Doctor of Philosophy from the University of London in Pathology & Toxicology.

Mr. Don Thomas is Vice President of Engineering for Nuclein. Mr. Thomas brings over 30 years of product development experience and a wealth of expertise in molecular diagnostics, cell-based assays, and semiconductor equipment/automation. Mr. Thomas has extensive experience in Executive Leadership, Project Management, and Quality, and have technical knowledge in areas such as IVD Regulatory Requirements, Microfluidics, Design Controls, and DFM, bringing a well-rounded IVD background to the Engineering team. Mr. Thomas’ decades of IVD experience include positions at Thermo Fisher Scientific, Mesa Biotech, ACEA Biosciences, and Nanogen. Mr. Thomas has Bachelor of Science degree in Mechanical Engineering from the California Polytechnic State University-San Luis Obispo.

Dr. Huiping Zhu is Vice President, Development – Biology of Nuclein. Prior to Nuclein, Dr. Zhu was Director of Assay R&D at Luminex Cooperation, leading molecular diagnostic product development and design verification in support of 510(k) and IVDR submissions. During her career, Dr. Zhu has been awarded an NIH Small Business Innovation Research (SBIR) grant, an R01 and an R21 research grant, and was a key contributor to multiple NIH and CDC research programs. Dr. Zhu has authored over 60 peer-reviewed scientific publications in the fields of molecular diagnostics, human genetics, and developmental biology. She graduated from Peking University Health Science Center with a Bachelor of Medicine (M.B.) degree, and subsequently earned her Ph.D. in Genetic & Molecular Epidemiology there as well.

Mr. Brian Estes is Chief People Officer of Nuclein. Prior to Nuclein, Mr. Estes was Director of Global Human Resources of Artivion, Inc.’s Asia Pacific and Latin America regions, leading global HR operations and rapid-growth global expansion efforts for the Class 3 medical device company. While at Artivion, Mr. Estes led the integration of the company’s acquisitions of On-X, a mechanical heart valve manufacturing facility in Austin, TX, and Jotec GmbH, a surgical prosthesis and endovascular device manufacturing facility in Hechingen, Germany. Prior to Artivion, Mr. Estes held Human Resources leadership positions at The Advisory Board Company (now Optum) and the Miami Marlins (Major League Baseball), leading rapid-growth and expansion efforts at each firm. He is certified as a Global Professional in Human Resources (GPHR), and Professional in Human Resources (PHR), and graduated cum laude from the University of Florida with a Bachelor of Science in Health and Human Performance.

Ms. Miranda Chavez is Associate Director of Program Management and Product Development of Nuclein. Prior to Nuclein, Ms. Chavez held Program Management leadership roles at Pattern Bioscience and Luminex Corporation, leading design transfer, and go-to-market, initiatives at each company. She established Luminex’s first Field Quality Assurance department, leading global root-cause analysis, and product resolution efforts, for field-related issues. Ms. Chavez has led EUA, IVD and CE IVD efforts for more than 20 medical diagnostic products and is credited with a CLSI guideline for Newborn Screening Programs. She graduated from Saint Edward’s University with a Bachelor of Science in Biochemistry, pre-medical.

Mr. Benjamin Treece is the Vice President of Quality & Regulatory Affairs.  Mr. Treece has held Quality & Regulatory leadership positions in the In Vitro Diagnostic (IVD) industry.  Most recently serving as the VP of Quality & Regulatory Affairs for diagnostic start-up Veravas establishing the company’s QMS and as Director, Quality & Regulatory Affairs, for Everly Health responsible for the Everywell Direct To Consumer (DTC) testing portfolio.  Prior to these recent experiences, Mr. Treece had a 15-year tenure at Luminex holding positions of increasing responsibility in the Quality organization ending his Luminex tenure as Director of Quality.  As Director of Quality at Luminex, he oversaw all Quality aspects for the Austin based manufacturing operations that included IVD Instruments, IVD Assays and life science instrument & reagent product lines.  In addition, Mr. Treece had global responsibility for Design Assurance and Document Control teams.  Prior to Luminex, Mr. Treece began his medical device experience as a Quality Assurance Chemist with an orthopedic implant manufacturer that is now Zimmer-Biomet.  Throughout his medical device career, he has served as a Management Representative and was the point of contact for third-party audits, including FDA inspections.  He graduated with a BS in Chemistry from University of Texas Austin and an MBA from West Texas A&M.

Dr. Michael Karberg is the Chief Scientist, and a founding team member, of Nuclein. In this role, he has been intimately involved in developing the company’s core technologies since its inception.  With decades of experience, Dr. Karberg has amassed an extensive background in nucleic acid assay development and optimization. In previous roles at Life Technologies and Thermo Fisher Scientific, he managed the research and development of animal health and food safety custom assays and products. He has developed over 100 assays, including those used to detect E. coli O157:H7, Salmonella, type 2 porcine circovirus, and porcine respiratory coronavirus. Dr. Karberg graduated from Ohio State University with a Bachelor of Science in Molecular Genetics and earned a Doctor of Philosophy in Molecular Biology from the University of Texas at Austin.

Mr. Michael Catalasan is Associate Director, Quality of Nuclein. Prior to Nuclein, Mr. Catalasan was Sr. Manager, Quality Engineering at Smith and Nephew, where he led teams across multiple sites in the U.S. and Costa Rica supporting manufacturing operations and R&D for the Sports Medicine and ENT franchises. In addition to his medical device experience, he has held positions of increasing responsibility in the pharmaceutical industry in Operations and Quality, including serving as Quality Management Representative in Missoula, Montana for Baxter and Manufacturing Quality Manager in Austin, Texas for Hospira. He graduated from the University of Texas at Austin with a Bachelor of Arts in Sociology.

Dr. Richard Crockett is a Co-Founder of Nuclein. Prior to Nuclein, Dr. Crockett was Co-Founder and President of Yorktown Technologies, leading the research, development, production, and regulatory efforts of the company, including the successful review of many FDA applications. Beyond Yorktown, Dr. Crockett is an experienced entrepreneur, who prior to co-founding Yorktown, co-founded ClassMap with Mr. Blake. He graduated from Yale University with an Intensive Bachelor of Science in Molecular, Cellular and Developmental Biology, later returning to Yale to earn his Medical Doctorate before surgical residency at Mt. Sinai Hospital in New York. Dr. Crockett holds 21 patents and is published in several peer-reviewed journals.

Walter M. Narajowski served as Chief Operating Officer of Minute Molecular since November, 2020 until the 2023 merger with Nuclein, LLC, where he now serves as a member of the Board of Directors. Mr. Narajowski continues to serve as Partner, LabDx a bio-tech consulting company since 2015.  Mr. Narajowski has over 25 years of senior level Medical device and In-Vitro Diagnostic industry experience.  Serving as Board member MDXHealth (MDX:EURONEXT) 2014 – 2019. Sr. Vice President & General Manager for Roka BioScience (ROKA:NASDAQ) from 2009 – 2015.  President/C.E.O. and Board Member of Pathway Diagnostics a biomarker development and testing company sold to Quest Diagnostics in 2008.  Vice President & General Manger of Focus Diagnostics, an Infectious Disease Reference Laboratory and IVD company.  Mr. Narajowski spent over 20 years with Abbott Laboratories (NYSE:ABT) in various positions of increasing responsibility vice president and general manager critical care products, general manager of physician office diagnostics and director of research and development with Abbott Diagnostics.  Mr. Narajowski received his M.S. in bioengineering from the University of Utah, and his B.S. in electrical engineering from the Illinois Institute of Technology.

Dr. Richard Crockett is a Co-Founder of Nuclein. Prior to Nuclein, Dr. Crockett was Co-Founder and President of Yorktown Technologies LP, leading the research, development, production and regulatory efforts of the company, including the successful review of multiple FDA applications. Beyond Yorktown, Dr. Crockett is an experienced entrepreneur, who prior to co-founding Yorktown Technologies, co-founded ClassMap with Mr. Blake. He graduated from Yale University with a Bachelor of Science in molecular, cellular and developmental biology, later returning to Yale to earn his medical doctorate before surgical residency at Mt. Sinai Hospital in New York. Dr. Crockett holds 22 patents and is published in several peer-reviewed journals.

Walter M. Narajowski served as Chief Operating Officer of Minute Molecular since November, 2020 until the 2023 merger with Nuclein, LLC, where he now serves as a member of the Board of Directors. Mr. Narajowski continues to serve as Partner, LabDx a bio-tech consulting company since 2015.  Mr. Narajowski has over 25 years of senior level Medical device and In-Vitro Diagnostic industry experience.  Serving as Board member MDXHealth (MDX:EURONEXT) 2014 – 2019. Sr. Vice President & General Manager for Roka BioScience (ROKA:NASDAQ) from 2009 – 2015.  President/C.E.O. and Board Member of Pathway Diagnostics a biomarker development and testing company sold to Quest Diagnostics in 2008.  Vice President & General Manger of Focus Diagnostics, an Infectious Disease Reference Laboratory and IVD company.  Mr. Narajowski spent over 20 years with Abbott Laboratories (NYSE:ABT) in various positions of increasing responsibility vice president and general manager critical care products, general manager of physician office diagnostics and director of research and development with Abbott Diagnostics.  Mr. Narajowski received his M.S. in bioengineering from the University of Utah, and his B.S. in electrical engineering from the Illinois Institute of Technology.

Sally McFall, Ph.D. serves as the Deputy Director of the Administrative Core and Director of the Technology Development/Refinement Core C-THAN. C-THAN was established in 2018 as part of the Point-of-Care Technologies Research Network created by National Institute of Biomedical Imaging and Bioengineering. Dr. McFall has extensive experience in technology development for low and middle income countries as the Director of Research of the Center for Innovation in Global Health Technologies (CIGHT) in the Department of Biomedical Engineering at Northwestern University. She possesses a broad background in molecular and clinical microbiology and has co-developed point-of-care assays and instruments side by side with CIGHT’s engineering team. She is also one of the co-founders and prior Chief Scientific Officer of Minute Molecular Diagnostics, Inc.